Physician profile
Cara Klein
NPI 1376066605
$1,527.94
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.39 · 2023: $638 · 2024: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.11 | 2023-2024 | |
| Novo Nordisk INC | $185.65 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $174.12 | 2022-2024 | |
| Lilly USA, LLC | $92.21 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.84 | 2022-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $72.88 | 2023-2024 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $70.88 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $70.15 | 2023-2024 | Gardasil 9, Proquad, Vaxelis |
| Axsome Therapeutics, INC. | $67.97 | 2023 | Auvelity |
| Lundbeck LLC | $62.55 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $53.33 | 2023-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $46.28 | 2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $42.03 | 2022 | |
| Dexcom, INC. | $38.22 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $32.08 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $29.32 | 2024 | |
| Organon LLC | $27.03 | 2023 | Nexplanon |
| Mylan Specialty L.P. | $24.73 | 2024 | Yupelri |
| Abbott Laboratories | $21.42 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $20.75 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.97 | 2024 | Caplyta |
| Phadia US INC. | $17.96 | 2023 | Immunocap |
| Astellas Pharma US INC | $17.52 | 2024 | Veozah |
| Daiichi Sankyo INC. | $16.93 | 2024 | Injectafer |
| Hologic Sales and Service, LLC | $16.45 | 2024 | Aptima |
| Idorsia Pharmaceuticals US INC | $16.18 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $15.38 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.